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Diabetic nephropathy affects 30–40% of diabetics
leading to end-stage kidney failure through progressive
scarring and fibrosis. Previous evidence suggests that
tissue transglutaminase (tTg) and its protein cross-link
product (-glutamyl)lysine contribute to the expanding
renal tubulointerstitial and glomerular basement mem-
branes in this disease. Using an in vitro cell culture
model of renal proximal tubular epithelial cells we de-
termined the link between elevated glucose levels with
changes in expression and activity of tTg and then, by
using a highly specific site directed inhibitor of tTg (1,3-
dimethyl-2[(oxopropyl)thio]imidazolium), determined the
contribution of tTg to glucose-induced matrix accumula-
tion. Exposure of cells to 36mM glucose over 96 h caused an
mRNA-dependent increase in tTg activity with a 25% in-
crease in extracellular matrix (ECM)-associated tTg and a
150% increase in ECM (-glutamyl)lysine cross-linking.
This was paralleled by an elevation in total deposited ECM
resulting from higher levels of deposited collagen and fi-
bronectin. These were associated with raised mRNA for
collagens III, IV, and fibronectin. The specific site-directed
inhibitor of tTg normalized both tTg activity and ECM-
associated (-glutamyl)lysine. Levels of ECM per cell re-
turned to near control levels with non-transcriptional re-
ductions in deposited collagen and fibronectin. No changes
in transforming growth factor 1 (expression or biological
activity) occurred that could account for our observations,
whereas incubation of tTg with collagen III indicated that
cross-linking could directly increase the rate of collagen
fibril/gel formation.We conclude that Tg inhibition reduces
glucose-induced deposition of ECMproteins independently
of changes in ECM and transforming growth factor 1 syn-
thesis thus opening up its possible application in the treat-
ment other fibrotic and scarring diseases where tTg has
been implicated.
Diabetic nephropathy (DN)1 accounts for 30–40% of patients
requiring renal replacement therapy (1–3). It is characterized
by an early thickening of tubular and glomerular basement
membranes due to an excessive accumulation of the extracel-
lular matrix and ultimately leads to progressive scarring and
fibrosis of the kidney (1–3). It also causes a significant increase
in the cardiovascular morbidity and mortality of diabetic pa-
tients. The incidence of diabetes and diabetic nephropathy
continues to rise worldwide. It is predicted that the number of
people with diabetes will continue to increase, reaching 221
million by 2010 (1).
Clinically, DN manifests itself by the onset of continuous
microalbuminuria followed by the appearance of persistent
proteinuria (2). This is followed by a progressive decline in
glomerular filtration rate ultimately leading to end-stage renal
failure. Although DN was traditionally considered to be pri-
marily a glomerular disease, it is now widely accepted that the
rate of deterioration of kidney function correlates best with the
degree of tubulointerstitial fibrosis (3). Consequently, in-
creased research has focused on the role of the tubular epithe-
lial cells, in particular the proximal tubular epithelial cells, in
the initiation of fibrosis.
In a recent study using the rat streptozotocin-induced hyper-
glycemic model of diabetes, we demonstrated elevated levels of
the protein cross-linking enzyme tissue transglutaminase (tTg)
in the peritubular interstitial space. This change in enzyme
distribution was paralleled by an increase in the (-glutamyl)-
lysine protein cross-link (4). We have shown similar changes in
fibrotic/scarred human kidney biopsy material (5) and in the
rat remnant kidney model of renal scarring (6, 7). In all cases
the up-regulation of tTg and its product correlated significantly
with increased interstitial fibrosis and scarring. In both animal
and human tissues, we demonstrated tubular epithelial cells to
be the major source of tTg.
Tissue transglutaminase belongs to a group of calcium-de-
pendent mammalian enzymes that have the capacity to irre-
versibly cross-link proteins through the formation of (-glu-
tamyl)lysine bonds (8). In addition to the potential role in
kidney scarring, elevated levels of tTg have been associated
with a number of other fibrotic diseases, including lung, liver,
and heart (9–11), where its ability to cross-link ECM is thought
to facilitate their increased deposition (12, 13) as well as their
increased resistance to the action of matrix metalloproteinases
(7). In addition to this proposed direct effect of tTg on matrix
accumulation, the enzyme has also been implicated in the
matrix storage and subsequent activation of the fibrogenic
cytokine, transforming growth factor 1 (TGF1), through the
cross-linking of the latent TGF1-binding protein (LTBP-1) to
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the ECM (14) thus facilitating its activation.
Given these potential direct and indirect contributions of tTg
to the pathogenesis of DN and the epidemiological evidence,
which indicates that the complications of diabetes are related
to poor glycemic control (2, 15), it was important to demon-
strate a molecular link between elevated glucose levels and
changes in the expression and action of tissue transglutami-
nase. To date, changes in tTg in relation to elevated glucose
conditions have only been observed in the pancreatic  cell (16).
The aim of the current study is to investigate the effects of
high glucose levels on tTg expression and activity in the well
characterized opossum proximal tubular epithelial cell line
(OK cells) (17–19). Initial studies were aimed at examining the
regulation of tTg expression in response to elevated glucose
concentrations, whereas subsequent studies examined how
changes in tTg could affect ECM deposition.
We demonstrate that elevated glucose concentrations stim-
ulate de novo synthesis of tTg, which is paralleled by an in-
crease in the expression of the ECM proteins fibronectin, col-
lagen III, and collagen IV, with a subsequent increase in the
deposition of total collagen and fibronectin. In the time frame of
our experiments (96 h) we observed no changes in the expres-
sion or presence of TGF1. We demonstrate, for the first time,
that the observed increase in the deposition of fibronectin,
collagen, and other matrix proteins induced by elevated glucose
conditions can be directly linked to their covalent cross-linking
via (-glutamyl)lysine bridges.
EXPERIMENTAL PROCEDURES
Experimental Protocol and Conditions—Opossum kidney proximal
tubular epithelial cells (OK PTCs) (European collection of cell cultures,
Cambridge, UK) were cultured in Dulbecco’s modified Eagle’s medium
containing 6 mM D-glucose (glucose-free Dulbecco’s modified Eagle’s
medium (Life Technologies) plus 1.1g/liter D-glucose), 100 units/ml pen-
icillin, 100 g/ml streptomycin, 20 mM glutamine, and 10% (v/v) fetal
calf serum in a humidified atmosphere at 5% (v/v) CO2.
For experimentation, 6 mM D-glucose was considered equivalent to
normal glycemic conditions. Glucose concentrations between 12 and 36
mM were considered to represent the clinical hyperglycemic environ-
ment. To achieve this, media was further supplemented with D-glucose
to the required concentration with a parallel flask containing an equiv-
alent concentration of L-glucose to control for osmolarity. All experi-
ments were carried out over a 96-h period with the alteration to glucose
at the time of plating. To ensure that glucose differentials were main-
tained throughout the experimental time period, media was assayed for
glucose daily using a glucose analyzer (Analox P-GM7 Micro-Stat) and
glucose added to compensate for cell usage.
For Tg inhibition studies, two highly specific active site-directed,
irreversible inhibitors were used. One, 1,3-dimethyl-2[(oxopropyl)thio]-
imidazolium (20, 21) was termed compound NTU283. The other, a
carboxybenzoyl-glutamylglycine analogue, was termed compound
NTU281.2 Both compounds were synthesized in-house. The inhibitor
NTU283 was added to 36 mM D-glucose culture media at the time of
plating to a final concentration of 33, 66, or 99 M. The inhibitor
NTU281 was used in the collagen fibrillogenesis assays at a concentra-
tion of 250 M.
Cell Number, Protein, DNA, and Viability Determination—Protein
concentrations were determined using protocols based on the Lowry
and the bicinchoninic acid assays. DNA was determined using the
Burton assay (diphenylamine). Viable cell numbers were measured by
the counting of cells using the trypan blue exclusion method. Cell
viability/cell leakage was also determined by measuring leakage of
lactate dehydrogenase into the cell culture medium (Cytotox 96 viabil-
ity assay kit, Promega, Southampton, UK).
Quantitation of Transglutaminase—Unless specified, cells were re-
moved with 2 mg/ml trypsin-2 mM EDTA then centrifuged at 300 g for
5 min, and the resultant pellet was washed in PBS. Cells were re-
suspended in 250 l of STE buffer (0.32 M sucrose, 5 mM Tris, 1 mM
EDTA) containing protease inhibitors phenylmethylsulfonyl fluoride (1
mM), benzamidine (5 mM), and leupeptin (10 g/ml) and homogenized
on ice.
For extracellular Tg, the media was collected and cells were removed
by centrifugation. The media was freeze-dried and re-suspended in 1/10
volume of STE buffer with protease inhibitors prior to analysis for
activity and tTg antigen (12).
Transglutaminase Activity—Transglutaminase activity was deter-
mined by the Ca2-dependent incorporation of [1,4-14C]putrescine (Am-
ersham Biosciences) into N,N-dimethylcasein as previously described
(6). Results were corrected to units/mg of protein (1 unit equals 1 nmol
of putrescine incorporated per hour at 37 °C).
tTg Western Blotting—Proteins were separated on a 10% (w/v) poly-
acrylamide gel and then electroblotted onto Hybond ECL (Amersham
Biosciences). The membrane was blocked with 3% nonfat dried milk,
0.05% (v/v) Tween 20 in PBS (milk-Tween-PBS) and then immuno-
probed with 0.2 g/ml of a anti-tTg monoclonal antibody (CUB7402,
Stratek Scientific, Luton, UK) at 4 °C overnight. Primary antibody
binding was revealed with 1.5 g/ml goat anti-mouse horseradish per-
oxidase secondary antibody (Dako, UK) for 1 h at room temperature and
visualized using ECL chemiluminescence (Amersham Biosciences).
Films were quantified by volume densitometry using a Bio-Rad GS-690
imaging densitometer and molecular analyst version 4 software
(Bio-Rad).
tTg ELISA—Ninety-six-well plates were coated with 100 l of 5
g/ml fibronectin overnight at 4 °C and blocked as above. Cell homoge-
nates or concentrated culture media (50 l) were incubated in triplicate
for 2 h at room temperature and then washed with milk-Tween-PBS.
Wells were then immunoprobed for tTg with 100 l of 0.2 g/ml of
anti-tTg monoclonal antibody CUB7402 overnight at 4 °C and revealed
with 100 l of 1.5 g/ml goat anti-mouse horseradish peroxidase-con-
jugated antibody for 2 h at room temperature using a TMB (3,3,5,5-
tetramethylbenzidine) substrate. 50 l of 2.5 M H2SO4 was used to stop
the reaction, and the absorbance was read at 450 nm.
Immunolocalization of tTg—OK cells were seeded and cultured in
8-well plastic chamber slides (Lab Tech, Scientific Laboratory Supplies,
Nottingham, UK), incubated for 96 h under experimental conditions
and immunoprobed for tTg, as previously described (22) using 0.6 g/ml
of anti-tTg monoclonal antibody CUB7042 overnight at 4 °C. Binding
was revealed using 3 g/ml goat anti-mouse secondary antibody conju-
gated to fluorescein and visualized using a Leica TCS-NT confocal laser
microscope with excitation at 488 nm and the emissions recorded at
530 nm.
Extracellular Matrix Analysis—For -(-glutamyl)lysine and hy-
droxyproline analysis, OK cells were grown in 10-cm Petri dishes and
solubilized with 1 ml of 0.1% (w/v) sodium deoxycholate-2 mM EDTA
(DOC-EDTA). The DOC-EDTA-soluble fraction was kept for protein
analysis (BCA assay) while the insoluble residue, remaining on the
plate and predominantly representing the ECM, was partially digested
with 0.2 mg/ml trypsin/1 mM EDTA and then scraped off. The fraction
was then freeze-dried. For tTg and fibronectin analysis, cells were
seeded in 96-well plates, and the DOC-EDTA-insoluble fraction was
immunoprobed directly on the plate.
-(-Glutamyl)lysine Levels—Freeze-dried proteins were suspended
in 0.1 M ammonium carbonate and subjected to exhaustive proteolysis
as previously described (23). Digests were freeze-dried again and re-
suspended in 0.1 N HCl. -(-glutamyl)lysine was analyzed by cation
exchange chromatography using an LKB 4151 amino acid analyzer
(Amersham Biosciences) using a modification of a lithium citrate buffer
method with an Ultrapac 8 cation exchange resin (8  0.5-m particle
size (23)). The detection of amino acids and peptides was undertaken by
a post column reaction with 600 mg/liter o-phthalaldehyde/5 ml/liter
2-mercaptoethanol, and the fluorescence was observed at 450 nm after
excitation at 360 nm using an LS1 detector (PerkinElmer Life Sciences)
with analysis of chromatograms by a Nelson 9000 A-D integrator and
software (Nelson Analytical). The amount of -(-glutamyl)lysine in
each sample was quantified by standard addition of 1 nmol of -(-
glutamyl)lysine dipeptide.
Quantitation of Hydroxyproline—DOC-EDTA-insoluble proteins
were acid-hydrolyzed in 6 N HCl overnight at 110 °C in an oxygen-free
environment. After freeze drying and re-suspending in H2O the hydro-
lysates were assayed for hydroxyproline by derivatization with
7-chloro-4-nitrobenz-2-oxa-1,3-diazole and separation by reverse phase
high-performance liquid chromatography (Beckman Instruments, High
Wycombe, UK) (24). Quantification was by absorption at 495 nm and
peak integration as above.
Extracellular Fibronectin and tTg—DOC-EDTA-insoluble proteins
were blocked with milk-Tween-PBS before the addition of either 0.2
g/ml of the monoclonal anti-tTg antibody CUB7042 or a 1:1000 dilu-
tion of rabbit anti-fibronectin (clone IST-1, Sigma) at 4 °C overnight2 Patent application number GB0314262.7, June 2003.
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(22). Primary antibody was revealed with 1.5 g/ml goat anti-mouse
IgG-horseradish peroxidase or goat anti-rabbit IgG-horseradish perox-
idase conjugates before the application of 70 g/ml TMB in phosphate-
citrate urea hydrogen peroxide buffer. The reaction was stopped with
2.5 M sulfuric acid, and the absorbance was read at 450 nm.
Measurement of ECM Collagen by 3H Proline Labeling—Cells were
seeded in 10-cm Petri dishes at a density of 3.75  106 per dish.
Deposited collagens were labeled by the addition of 20 l of [2,3-
3H]proline (1.0 mCi/ml, ICN) at the time of plating. After 96 h the media
was removed, and cells were washed with PBS. Cells were then re-
moved with 2 ml of 0.25 M ammonium hydroxide in 50 mM Tris, pH 7.4,
at 37 °C for 10 min. The soluble fraction was collected, and protein
concentration was determined using the BCA assay. The dishes were
washed extensively with increasing volumes of PBS before the ECM
was solubilized with 2 ml of 2.5% (w/v) SDS in 50 mM Tris, pH 6.8. The
dish was then scraped to ensure complete removal of the ECM, and 200
l was measured for radioactivity in a scintillation counter.
Collagen Fibrillogenesis Assay—Collagen fibrillogenesis was moni-
tored using a spectrophotometric method (25). Type III collagen (Sigma
C3511) was solubilized in 0.2 M acetic acid at a concentration of 5 mg/ml
at 4 °C with constant stirring for 24 h. Initiation of fibrillogenesis was
by neutralization of the collagen mixture by the addition of 10 Dul-
becco’s modified Eagle’s medium and 0.2 M HEPES buffer to final
concentrations of 1 and 0.02 M, respectively. Addition of CaCl2 to 5 mM
and dithiothreitol to 5 mM was made immediately after neutralization
and before addition of guinea pig liver tissue transglutaminase (Sigma
T5398,1000 units/mg). Fibril formation after neutralization was mon-
itored by measuring absorbance at 325 nm using a PYEUnicam SP1800
UV spectrophotometer.
mRNA Analysis—Total RNAwas extracted from at least 5 106 cells
using TRIzolTM (Invitrogen) and quantitated by optical density at 260
nm. 15 g of total RNA was then run on a 1.2% (w/v) agarose/MOPS/
formaldehyde gel and then capillary blotted on to Nylon (Roche Ap-
plied Science) and cross-linked with 70 mJ/cm2 UV radiation (UV cross-
linker, Amersham Biosciences). This was then probed with [-32P]dCTP
random primed labeled (Prime a gene, Promega, UK), sequence-specific
DNA probes for tTg (7), collagens III (26) and IV (27), fibronectin (28),
and TGF1 (29) before exposure to BioMax MS film. The resulting
autoradiographs were then quantified by scanning densitometry using
a Bio-Rad GS-690 densitometer and Molecular Analyst version 4 soft-
ware. Transcript size was determined by comparison to RNA molecular
weight markers (Promega, UK) using the same analysis package. Val-
ues were then corrected for loading using repeat probings with GAPDH.
Detection of Active TGF—Active and total TGF (heat-activated)
was determined using the mink lung epithelial cell assay whereby mink
lung epithelial cells are stably transfected with a construct consisting of
the TGF1 promoter region of plasmin activator inhibitor ligated to the
luciferase reporter construct (30). Media (serum-free) from OK cells
grown under increased glucose concentrations was collected and ap-
plied to mink lung epithelial cells overnight. The media was then
removed, and the cells were lysed and assayed for luciferase activity
using a luciferase assay kit (Promega) and luminometer (Anthos Lab
Tec Instruments, Salzberg, Austria), as per the manufacturer’s instruc-
tions. Commercially available TGF1 was used as a positive control.
Collagen Secretion—Cells were grown for 96 h with [2,3-3H]proline
(Amersham Biosciences) added to the culture media at a final concen-
tration of 75 kBq/ml. To determine the total amount of [2,3-3H]proline-
labeled proteins present in the media, 25 l of media was precipitated
onto 3MM filter paper using ice-cold 10% trichloroacetic acid, washed
three times in 5% trichloroacetic acid and twice in ethanol before
counting in a scintillation counter. To determine the collagen compo-
nent of this, a parallel sample of media was digested with 30 units/ml
of chromatography-purified (i.e. free of proteases and clostripain) bac-
terial collagenase (Sigma) for 15 min at 37 °C in 50 mM Tris, pH 7.4, 10
mM CaCl2, 0.2 M NaCl before precipitation with trichloroacetic acid. The
overall amount of collagen-labeled material in the media was calculated
by subtracting the counts following collagenase digestion from the total
labeled protein.
Fluorography of Secreted Collagens—Media from cells grown in 75
kBq/ml labeled proline (Amersham Biosciences) for 96 h was precipi-
tated using 4 volumes of acetone, washed 3, and then resuspended in
1% (w/v) SDS, 50 mM Tris, pH 7.4, 1 mM EDTA. 50 l of protein was
then separated on 10% (w/v) polyacrylamide gels using an interrupted
SDS-PAGE (31, 32) approach to allow clear separation of collagen I and
III bands. The gel was then dried under vacuum at 80 °C and exposed
to BioMax MS film at 70 °C for 4 weeks.
Data Analysis—All data are shown as means  S.E. Experimental
groups were compared using Student’s t test with unequal variance. p
0.05 was taken as statistically significant.
RESULTS
Effect of High Glucose on Cell Proliferation and Viability—
Increasing the concentration of glucose from 6 to 36 mM in the
culture media of OK PTCs over a 96-h period caused a dose-
dependent increase in viable cell numbers with no significant
changes observed in cell leakage (lactate dehydrogenase ratio)
and cell viability (Trypan Blue) (Table I).
Effect of High Glucose on Transglutaminase—Increasing the
media concentration of glucose caused a dose-dependent in-
crease in the cellular activity of Tg in OK cells (Fig. 1a). This
was shown to be due to increases in tTg protein measured by
both ELISA (Fig. 1b) and Western blotting (Fig. 1c), which was
mRNA-dependent (Fig. 1d). Immunoprobing of cells for tTg
showed that large increases in antigen were localized to cell
clusters (Fig. 1e). Measurement of Tg activity and tTg antigen
in the culture media demonstrated that changes in intracellu-
lar tTg were carried through to the extracellular environment
with Tg activity increasing from 1.65  0.21 to 2.5  0.27
units/106 cells and tTg antigen from 1.51  0.07 to 3.3  0.41
ng/106 cells as glucose concentration was increased from 6 to 36
mM, respectively.
Effects of High Glucose on the Extracellular Matrix—Follow-
ing the removal of cells using a deoxycholate-EDTA solution
(DOC-EDTA), the remaining extracellular proteins (i.e. ECM)
increased in response to glucose from 1.1  0.1 mg/107 cells at
6 mM glucose to 2.5  0.2 mg/107 cells at 36 mM glucose (Fig.
2a). Analysis of fibronectin (Fig. 2b) and total collagen (hy-
droxyproline) (Fig. 2c) showed that both these proteins were in
part responsible for increased levels of ECM proteins. Northern
blot analysis indicated that these increasesweremRNA-dependent
with specific changes in fibronectin, collagen I and IVmRNA levels
(Fig. 2, d–f). There was no measurable change in TGF1 mRNA or
active TGF1 present in the cell culture medium (data not shown)
suggesting these increases were not mediated via changes in
TGF1 synthesis.
Analysis of the recovered ECM by reverse phase high-per-
formance liquid chromatography showed a significantly in-
creased level of -(-glutamyl)lysine cross-linking at high glu-
cose concentrations in comparison to 6 mM glucose-cultured
cells where -(-glutamyl)lysine was not detectable under the
conditions used (Fig. 3b). Further analysis of the ECM by
ELISA for tTg showed a corresponding increase to that of
TABLE I
Effect of high glucose on cell proliferation and viability
Extracellular D-glucose Cell number Total protein Total DNA Intracellular D-glucose LDH ratio Trypan bluestaining
mM 106 mg/plate g/plate M %
6 1.45  0.15 0.23  0.06 18.2  1.3 0.87  0.18 96.6  0.4 95.4  2.17
24 1.59  0.17a 0.34  0.08a 19.9  0.7 1.36  0.19 97.3  0.8 96.6  1.3
36 1.83  0.30a 0.38  0.1a 22.9  2.3a 1.79  0.19 97.4  0.7 94.6  2.8
a p  0.05
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-(-glutamyl)lysine (Fig. 3a) indicating that tTg is a strong
candidate for the increased cross-linking.
Inhibition of Transglutaminase Activity—To determine if
tTg-induced ECM cross-linking affected the accumulation of
ECM proteins in response to high glucose in OK cells, cells
were incubated in the presence of the specific irreversible site-
FIG. 1. The effect of high glucose on transglutaminase levels in OK cells. OK cells were incubated for 96 h in a range of glucose
concentrations and cell homogenates assayed for Tg activity by putrescine incorporation assay (a), tTg antigen by ELISA (b), and Western blotting
(c), mRNA by Northern blotting (d) and localized using immunofluorescence (e) using an fluorescein isothiocyanate label with propidium iodide
stained nuclei at 400 magnification. Data in parentheses represent volume density measurements, which for protein are corrected for protein
loading, and mRNA analysis is corrected for loading using GAPDH. All data represent mean values S.E. from at least three separate experiments
performed in triplicate.
FIG. 2. The effect of high glucose on the extracellular matrix in OK cells. OK cells were incubated for 96 h in 6, 24, and 36 mM glucose.
Cells were then removed using deoxycholate-EDTA. The insoluble protein remaining on the plate (ECM) was recovered, and the total amount of
protein was assayed (Lowry) and expressed per 1  107 cells (a). Parallel plates were assayed more specifically for fibronectin by ELISA (b) and
collagen using hydroxyproline (c). Northern blot analysis was used to ascertain if any of these changes were mRNA-dependent (d) with data in
parenthesis representing volume density measurements corrected for loading using GAPDH. All data represents mean values  S.E. from at least
three separate experiments performed in triplicate.
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directed Tg inhibitor (NTU283). This led to a dose-dependent
decrease in Tg activity from the elevated level observed at 36
mM glucose (Fig. 4a). At the highest dose of inhibitor used there
was no effect on total viable cell numbers, cell leakage, or cell
viability (data not shown) when compared with the respective
control cells without inhibitor.
Effect of Tg Inhibition on Glucose-mediated ECM Accumula-
tion—Following removal of OK cells grown in 36 mM glucose
with DOC-EDTA, analysis of the recovered ECM showed a
corresponding reduction in the level of -(-glutamyl)lysine
isodipeptide cross-link per milligram of protein with increasing
concentration of Tg inhibitor (Fig. 4b). However, even with the
highest dose employed, levels could not be normalized to those
found in cells grown at 6 mM glucose. The reduction in -(-
glutamyl)lysine isodipeptide also corresponded to a reduction
in the total amount of ECM protein deposited per cell (Fig. 5a).
More specific analysis of the ECM for total collagen (hy-
droxyproline) (Fig. 5, b–d) and fibronectin (Fig. 5e) showed a
corresponding decrease in both these ECM proteins with in-
creasing concentrations of Tg inhibitor 283. To confirm the
observed reduction in total collagen deposited, Tg inhibition in
a high glucose environment was repeated but using [3H]proline
labeling of cells to measure the deposition of collagen in the
ECM. Tg inhibition was highly effective in reducing the
amount of label incorporated when normalized per cell (Fig. 5f).
To rule out the possibility that the Tg inhibitor NTU283
might be affecting transcription of the measured ECM pro-
teins, TGF1 or tTg, Northern blot analysis was performed on
the inhibitor-treated cells. In no case was any significant alter-
ation in the mRNA levels of collagen III, IV, fibronectin,
TGF1, or tTg noted (Fig. 6) indicating that the effect of Tg
inhibition is not occurring at the transcriptional level.
To rule out any possible effects of the Tg inhibitor on collagen
secretion [3H]proline was used to label collagen in OK cell
cultures grown at 30 mM glucose for 96 h with or without Tg
inhibitor NTU283. The total counts adjusted per milligram of
cellular protein for the collagenase-degradable protein found in
the medium was 309,665  29,604 for the 30 mM glucose
medium without inhibitor and 334,183  29,604 with inhibitor
obtained from three separate experiments. Because these val-
ues are not significantly different, it can be concluded that the
Tg inhibitor NTU283 does not affect collagen deposition
through its effects on cell secretion. Interestingly, when these
values for secreted collagen are compared with the amount of
collagen actually deposited (Fig. 5f), it can be seen that only a
low percentage of the collagen found in the medium (0.6%) is
actually deposited. To confirm the findings that the Tg inhibi-
tor does not affect collagen secretion, fluorography was under-
taken on the labeled proteins found in the medium of treated
cells following separation of proteins by SDS-PAGE. Despite
the presence of multiple bands shown by fluorography (not
shown), it was possible to observe particularly intense bands
that ran parallel to purified collagens (1)III and (1,2)IV, with
weaker bands that could be associated with collagen I chains.
FIG. 3. Transglutaminase cross-
linking in the extracellular matrix in
OK cells. OK cells were incubated in a
range of glucose concentrations for 96 h.
Cells were then removed using deoxy-
cholate-EDTA. The insoluble protein re-
maining on the plate (ECM) was then as-
sayed for tTg using a direct ELISA (a) or
recovered, exhaustively digested, and (-
glutamyl)lysine dipeptide cross-link meas-
ured by cation exchange on an amino acid
analyzer (b). All data represent mean val-
ues  S.E. from at least three separate ex-
periments performed in triplicate.
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There was no obvious difference in either the banding pattern
or intensity between cells grown in 30 mM glucose with or
without NTU283 (data not shown).
Effect of Transglutaminase on in Vitro Type III Collagen
Fibrillogenesis—To determine whether Tg could affect the dep-
osition rate of collagen into the ECM, an in vitro assay of
collagen fibril formation was performed. The addition of Tg to
neutralized type III collagen in vitro resulted in an increase in
the rate of fibril formation in a dose-dependent manner (Fig. 7).
A significant increase (p  0.05) in the final level of turbidity
indicative of fibril formation was also noted with Tg treatment.
Inhibition of transglutaminase activity using the Tg inhibitor
confirmed that these effects were solely due to Tg activity.
DISCUSSION
Although the etiology of DN is multifactorial, it is now rec-
ognized that the degree of glycemic control will play a major
role in the rate of progression of kidney scarring (33). Further-
more, it is becoming apparent that the progression of renal
dysfunction correlates best with the degree of interstitial fibro-
sis rather than glomerular pathological changes (34). In previ-
ous studies using both animal models (4) of DN and the anal-
ysis of human biopsy material (5), we demonstrated that the
Ca2-dependent protein cross-linking enzyme tTg may contrib-
ute to the pathological changes occurring in the renal intersti-
tium by increasing matrix deposition either directly through
the cross-linking of matrix proteins (7, 13) and/or indirectly
through its ability to activate matrix associated TGF1 (22). As
a consequence, we have now investigated how elevated glucose
concentrations may alter proximal tubular cell (PTC) function
in relation to tTg expression and activity and how this in turn
may affect changes in the ECM. In the well characterized OK
PTC cell line, we demonstrated that elevated glucose levels
maintained over a 96-h period lead to a mRNA-dependent
increase in tTg activity and antigen. Importantly, as previously
observed in other cells expressing high levels of tTg (12, 33), the
increase in tTg expression resulted in an increase in the en-
zyme translocated into the extracellular space by a regulated
but unknown process (tTg does not contain a conventional
leader sequence for secretion via the Golgi/endoplasmic retic-
ulum route) (35, 36, 37), because no loss of cell viability or
increased cell leakage was induced by incubation with high
glucose. This increase in tTg seems to be directly related to the
stress imposed by the elevated glucose and not due to the
effects of up-regulated TGF1, a known fibrogenic cytokine
capable of inducing tTg expression (38, 39). Over the 96-h
period no changes in TGF1 expression or biologically active
FIG. 4. Ability of compound 283 to
inhibit Tg activity and prevent ECM
cross-linking. OK cells were incubated
in 36 mM glucose for 96 h in the presence
of Tg inhibitor 283 to a final concentration
of 33, 66, or 99 M. Cells were then har-
vested, and the cellular Tg activity was
measured using a putrescine incorpora-
tion assay (a). In parallel plates, cells
were removed using deoxycholate-EDTA,
and the insoluble protein remaining on
the plate (ECM) was recovered, exhaus-
tively digested, and (-glutamyl)lysine
dipeptide cross-link measured by cation
exchange on an amino acid analyzer (b).
All data represent mean values  S.E.
from at least three separate experiments
performed in triplicate.
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cytokine were detectable in the OK cells under the conditions
that we used. This is in agreement with studies using human
proximal tubular epithelial cells, which demonstrated that pro-
longed exposure to high glucose of 7 days was required to
increase TGF1 production (40). Changes in TGF1 were
therefore not responsible for the observed increases in the
expression of fibronectin, collagen III, and collagen IV, which
was reflected in the parallel increases in total ECM, collagen,
and fibronectin deposited in cells exposed to high glucose.
Importantly, these glucose-induced changes in ECM deposi-
tion correlated well with the increase in the matrix-associated
(-glutamyl)lysine covalent cross-link, suggesting a direct in-
volvement of tTg in matrix accumulation. In previous studies,
we have demonstrated that increased expression of tTg in
Swiss 3T3 fibroblasts leads to an increase in the deposition and
cross-linking of fibronectin and the latent TGF1 binding pro-
tein (22). We have also shown that exogenous addition of tTg to
primary human dermal fibroblasts leads to an increase in the
accumulation of matrix-associated collagen (12).
To test whether the glucose-induced increase in the deposi-
tion of total ECM and total collagen in the OK cells were
directly related to the Tg-mediated cross-linking observed, the
specific site-directed irreversible inhibitor of transglutaminase
1,3-dimethyl-2[(oxopropyl)thio]imidazolium (IC50 50 M) was
included in the culture medium during exposure of cells to high
glucose. Inclusion of the inhibitor (33–99 M) led to a dose-de-
pendent inhibition of tTg activity measured in cell homoge-
nates with 70% inhibition obtained at 99 M. Of relevance,
the concentration of Tg-mediated (-glutamyl)lysine cross-
link found in the ECM was reduced by around 50% when cells
were incubated with the inhibitor. This inhibition of Tg-medi-
ated cross-linking was reflected by comparable reductions in
total ECM protein and fibronectin confirming the importance of
Tg-mediated cross-linking in ECM accumulation. An even
greater inhibitory effect (around 90%) was observed in total
ECM-associated collagen, the major protein associated with
scarring, when measured by two independent methods. The
finding, that the site-directed inhibitor of Tg, at the concentra-
tions used, had no effect on the transcription of collagen III,
collagen IV, and fibronectin or on the secretion of collagen into
the extracellular environment, indicates that its mode of action
in reducing levels of ECM is unlikely to be mediated via either
reducing the expression of these proteins or by affecting
their secretion.
Our results therefore indicate a key role for Tg-mediated
cross-linking in the pathological events associated with in-
creased ECM deposition induced by elevated glucose in OK
PTCs thus providing the molecular link between hyperglyce-
mia and elevated tTg activity. Apart from factor XIII A subunit
and the prostate transglutaminase for which there is no asso-
ciated evidence within renal proximal tubular cells, tissue
transglutaminase is the only known mammalian transglutami-
nase to be secreted into the extracellular space. The identifica-
tion of increased levels of tTg in the ECM and medium of OK
PTCs after exposure to elevated glucose also confirms the in-
volvement of tTg as the key transglutaminase responsible for
the changes in the ECM that we observe. In human dermal
fibroblasts, we demonstrated that exogenous addition of tTg
not only increased collagen deposition, but it also slowed down
its rate of turnover (12), which is in part due to the increased
resistance of cross-linked collagen to proteolytic degradation
(7). Using in vitro studies, we have demonstrated that tTg-
mediated cross-linking of collagen I can lead to 0.5 mol of
(-glutamyl)lysine incorporated into 1 mol of collagen I mon-
omer (42). In the present study we demonstrate that tTg-
mediated cross-linking of collagen III can increase both the rate
FIG. 5. Effect of Tg inhibition on glucose-induced ECM levels. OK cells were incubated in 36 mM glucose (Glu) for 96 h in the presence of
Tg inhibitor 283 to a final concentration of 33, 66, or 99 M. Cells were removed using deoxycholate-EDTA, the insoluble protein remaining on the
plate (ECM) was recovered, and the total amount of protein was assayed (Lowry) and expressed per 1  107 cells (a). Parallel plates were assayed
more specifically for collagen (hydroxyproline (hxyprol)) (b–d) and fibronectin (e). Hydroxyproline was normalized to ECM protein (b), cell number
(c), and DNA (d). Changes in collagen were confirmed using additional plates grown in the presence of [3H]proline whereby the cells were removed
with ammonium hydroxide, and the recovered ECM scintillation was counted and expressed per milligrams of cell protein (f). All data represents
mean values  S.E. from at least three separate experiments performed in triplicate.
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and amount of collagen fibril formation. The speed at which
this occurs, i.e. over 5 min, suggests that very little cross-link is
required. This is confirmed by the finding that in the high
glucose-treated OK PTCs 0.3 nmol of (-glutamyl)lysine was
found per milligram of total ECM. However, this value is likely
to vary quite considerably in the cell culture, because enzyme
expression as defined by immunofluorescence was much more
concentrated in specific areas after glucose exposure. Assuming
collagen III is the preferred collagen substrate as demonstrated
by others (43) and that this protein makes up around 25% of
the total ECM, then this value equates to around 1 cross-link
per 2–3 collagen molecules of 300,000 Da. However, the ability
of the site-directed inhibitor of tTg activity to reverse this effect
both in vitro and in the cell model, confirms that transamida-
tion is essential for any effect on fibril formation to occur.
Importantly, transglutaminase-mediated cross-linking of colla-
gen is able to increase both the rate and level of its deposition
as well as reducing its rate of degradation thus tipping the
balance toward collagen accumulation.
tTg-mediated cross-linking can therefore affect both the rate
of ECM deposition as well as its clearance; either of which can
account for the reduction in ECM levels following Tg inhibition.
Laurent et al. (44, 45) suggested that ECM components are
synthesized in excess of requirements, a finding that is con-
firmed by our studies when analyzing the amount of collagen
secreted into the culture medium compared with that which is
FIG. 6. Effect of Tg inhibition on
tTg, TGF1, and ECM protein mRNA
expression. OK cells were incubated in
36 mM glucose for 96 h in the presence of
Tg inhibitor 283 to a final concentration of
33, 66, or 99 M. Cells were harvested,
and total RNA was extracted and sub-
jected to Northern blot analysis using
specific [32P]dCTP random-primed cDNA
probes. Representative autoradiographs
are shown for collagens III and IV, fi-
bronectin, tTg, and TGF1. Repeat prob-
ings using GAPDH acted as a loading con-
trol. Arbitrary volume density values
corrected for GAPDH are shown in
parentheses.
FIG. 7. Effect of tTg on type III col-
lagen fibrillogenesis. Collagen (3 mg/
ml) was neutralized as outlined under
“Experimental Procedures” and then
treated with 0, 50, or 250 g/ml tTg.
Transglutaminase inhibitor (R281 500
M) was used to confirm that the effects
were due to transglutaminase activity.
The absorbance at 325 nm was measured
using a PYE Unicam SP1800 UV spectro-
photometer. The temperature was con-
trolled at 25 °C using a Techne C-85A cir-
culator. Results are from the average of
three independent experiments.
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deposited. Hence the rate of deposition of available components
is crucial to ECM levels. Clearly an enzyme capable of cross-
linking proteins leading to their increased deposition and pro-
teolytic stability would incorporate more proteins into the
available matrix by non-conventional routes. Work by Kleman
et al. (13) also showed that tTg could stabilize fibrils of collagen
V and XI independently of lysyl oxidase further indicating that
tTg can provide such a route. This is likely to be applicable to
other collagens and ECM components that are tTg substrates.
In conclusion, when taken together our data strongly support
the hypothesis that increased expression of tTg in renal prox-
imal epithelial cells induced by elevated glucose is a key con-
tributory factor in the pathological events associated with the
progression of interstitial fibrosis and scarring in diabetic ne-
phropathy. As such this enzyme presents itself as a potential
therapeutic target for the treatment of this disease and other
fibrotic and scarring conditions where tTg has been implicated
(9–11). The availability of specific inhibitors makes this task
closer to clinical translation.
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